31 patents
Utility
Antibody Compositions and Methods of Use Thereof
4 Jan 24
The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants.
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Filed: 21 Aug 23
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
4 Jan 24
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 23 Jun 23
Utility
Dosing Regimen
21 Dec 23
Provided are combination dosing regimens comprising administering cabotegravir and hyaluronidase.
Kelong HAN, Andrew Weber, Michael James Labarre, Jessica Brehm, Nima Akhavein, Emile Velthuisen
Filed: 12 Jun 23
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
9 Nov 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Dec 22
Utility
SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
12 Oct 23
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies.
Louis Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 22 Jun 23
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
21 Sep 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 12 Dec 22
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
21 Sep 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Dec 22
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
14 Sep 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 21 Dec 22
Utility
Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
15 Aug 23
Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies.
Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
Filed: 2 Oct 20
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
10 Aug 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Dec 22
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
6 Jul 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 19 Dec 22
Utility
Compositions of Adenosine DEAMINASE-2 (ADA2), Variants Thereof and Methods of Using Same
29 Jun 23
Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates.
Christopher D. THANOS, Lin WANG, H. Michael SHEPARD
Filed: 28 Nov 22
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
18 May 23
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge WEI, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 15 Dec 22
Utility
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
21 Feb 23
Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates.
Christopher D. Thanos, Lin Wang, H. Michael Shepard
Filed: 29 Mar 18
Utility
Combination Therapy with a Hyaluronan-degrading Enzyme and an Immune Checkpoint Inhibitor
24 Nov 22
Provided are methods of treatment of cancers with combinations of and compositions containing a soluble hyaluronidase, such as a polymer-modified soluble hyaluronidase, and an immune checkpoint inhibitor for treating cancers, including solid and non-solid tumors.
Sanna ROSENGREN, H. Michael SHEPARD, Curtis B. THOMPSON
Filed: 27 Jun 22
Utility
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
16 Aug 22
Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors.
Sanna Rosengren, H. Michael Shepard, Curtis B. Thompson
Filed: 27 Feb 17
Utility
Methods of Treating Tumors
28 Jul 22
The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.
Masano Huang, Thomas Arthur Haby, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Filed: 27 Dec 21
Utility
Antibody Compositions and Methods of Use Thereof
28 Jul 22
The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants.
Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
Filed: 27 Dec 21
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
16 Sep 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 21 May 21
Utility
PH20 Polypeptide Variants, Formulations and Uses Thereof
9 Sep 21
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided.
Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Filed: 21 May 21